Literature DB >> 1313894

Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.

L Brooks1, Q Y Yao, A B Rickinson, L S Young.   

Abstract

Epstein-Barr virus (EBV) genome-positive nasopharyngeal carcinomas (NPCs) regularly express the virus-coded nuclear antigen EBNA1, but not other EBNAs, and a subset of tumors also appear to be latent membrane protein LMP1 positive; the status of NPCs with respect to a second virus-coded latent membrane protein LMP2 is unknown. In the present work the EBV-NPC cell interaction has been analyzed at the RNA level with reverse transcription and polymerase chain reaction-based amplification to detect specific latent viral mRNAs. All four transplantable NPC cell lines studied and 17 of 18 fresh snap-frozen NPC biopsy specimens expressed an EBNA1 mRNA with a BamHI Q/U/K splice structure exactly like that recently identified in group I Burkitt's lymphoma (BL) cell lines and shown to be driven from a novel viral promoter, Fp. The BamHI Y3/U/K-spliced EBNA1 mRNA characteristic of virus-transformed B-lymphoblastoid cell lines (LCLs) was never found in NPCs. These same NPC biopsy specimens were then analyzed for evidence of the various LMP transcripts which are constitutively expressed in LCLs but down-regulated in BL cells. While only 3 of 18 tumors gave a clear LMP1 mRNA-specific signal after first-round amplification with either of two sets of polymerase chain reaction primers, the majority proved to be LMP1 mRNA positive after second-round amplification with nested primers. A rather similar pattern of results was obtained with respect to LMP2B mRNA expression, such transcripts being detectable only in a subset of tumors, and then at apparently low levels. In contrast, clear evidence of LMP2A mRNA expression was obtained in 17 of 17 fresh biopsies. The predominant form of EBV infection in NPCs, with coexpression of EBNA1 and LMP mRNAs, is therefore quite distinct from that seen in BL cells (in which EBNA1 is the only expressed mRNA) and in LCL cells (in which all six EBNA and three LMP transcripts are present). This third form of EBV latency may not be restricted to NPC but may have more general relevance in the context of EBV infection in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313894      PMCID: PMC241023     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element.

Authors:  R Fåhraeus; A Jansson; A Ricksten; A Sjöblom; L Rymo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.

Authors:  C D Gregory; M Rowe; A B Rickinson
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

4.  Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein.

Authors:  S D Abbot; M Rowe; K Cadwallader; A Ricksten; J Gordon; F Wang; L Rymo; A B Rickinson
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

5.  Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation.

Authors:  C W Dawson; A B Rickinson; L S Young
Journal:  Nature       Date:  1990-04-19       Impact factor: 49.962

6.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

7.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

8.  Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6.

Authors:  J B Wilson; W Weinberg; R Johnson; S Yuspa; A J Levine
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

9.  Differential expression of Epstein Barr viral transcripts for two proteins (TP1 and LMP) in lymphocyte and epithelial cells.

Authors:  P R Smith; B E Griffin
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

10.  One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain.

Authors:  K Hennessy; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

View more
  149 in total

1.  Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes.

Authors:  Y Chang; C H Tung; Y T Huang; J Lu; J Y Chen; C H Tsai
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 3.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

4.  Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt.

Authors:  F Scholle; K M Bendt; N Raab-Traub
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 5.  The expression and function of Epstein-Barr virus encoded latent genes.

Authors:  L S Young; C W Dawson; A G Eliopoulos
Journal:  Mol Pathol       Date:  2000-10

6.  The mechanism of Epstein-Barr virus infection in nasopharyngeal carcinoma cells.

Authors:  C T Lin; C R Lin; G K Tan; W Chen; A N Dee; W Y Chan
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

7.  The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.

Authors:  R Longnecker; C L Miller; X Q Miao; A Marchini; E Kieff
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

8.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.

Authors:  B C Schaefer; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

10.  Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes.

Authors:  C L Miller; R Longnecker; E Kieff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.